News

It's been a less-than-thrilling past few months for investors in Palantir Technologies (NASDAQ: PLTR), but understandably so. Shares of the artificial intelligence software powerhouse remain

For the first 10 years of its publicly traded life, leading animal healthcare stock Zoetis (NYSE: ZTS) easily outpaced the S&P 500, rising 480% and doubling the index's total returns. However, since

It's been a rough past 12 months for UnitedHealth Group (NYSE: UNH), with the stock price down nearly 34% (through Jan. 20). This is not-so-great news for a company that's had its fair share of

If you're a retiree, you may be concerned about how safe it is to invest in the stock market right now. Valuations are high, economic conditions are questionable, and it's getting more difficult to

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to

There's nothing quite like making money while you sleep. And investing in dividend stocks is a great way to do that. However, with so many dividend payers, it can be hard to know which one to pick.

The market had no love for Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) last year, as both companies lagged broader equities and lost significant market value. This might make

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do

Last year was a challenging one for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech. The company made little clinical progress and, in fact, one of the major data readouts it released was not

For the last three years, the S&P 500 index has generated abnormally high returns thanks to absurd levels of demand for artificial intelligence (AI). In particular, the technology and infrastructure

Explore the exciting world of Insulet (NASDAQ: PODD) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market

Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label

Shares of Rapt Therapeutics (NASDAQ: RAPT) surged on Tuesday after the immunology specialist struck a deal to be acquired by British pharmaceutical leader GSK (NYSE: GSK) for $2.2 billion.

By the

There's no two ways about it. Nvidia has been the centerpiece of the artificial intelligence (AI) revolution thus far. Its processors are the heart and soul of most of the planet's AI data centers

For the last three years, there has been no company in the semiconductor industry as dominant as Nvidia (NASDAQ: NVDA). The company kick-started the artificial intelligence (AI) revolution with its

Investors in biotechnology company Viking Therapeutics (NASDAQ: VKTX) had a rollercoaster ride in 2025, driven by clinical trial data, or rather, the perception of the clinical trial data. Let's

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD), Riot Platforms (NASDAQ: RIOT), and other AI stocks. To learn more, check out the short video, consider

There's a boom going on in much of the U.S., and it's not just tied to technology. Housing shortages have spurred residential homebuilding activity, particularly in fast-growing areas like the Sun

Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights

Pfizer (NYSE: PFE) is in the Wall Street doghouse. It is currently viewed as an also-ran in the drug sector, lagging far behind peers like Eli Lilly (NYSE: LLY) in various categories, including the

2026 is shaping up to be another fantastic year for the stock market, especially with the amount of artificial intelligence (AI) spending going on. I think there are several stocks bound to rocket

Broader equities almost always deliver positive returns over the span of a decade. That's been the case for over 100 years, other than a few 10-year periods that were rocked by significant economic

The days when you had to rely on two human beings yelling at each other across a trading floor to buy 100 shares of stock are long gone, and the electronic trading platforms that have largely